Skip to main content
Journal cover image

Future therapy of hepatitis C.

Publication ,  Journal Article
McHutchison, JG; Patel, K
Published in: Hepatology
November 2002

Currently available therapies for the treatment of chronic hepatitis C are effective in half of patients, but are expensive, often poorly tolerated, and unsuitable for certain patient populations. The ideal therapy would be highly effective, orally bioavailable, have minimal side effects, be cost effective, and suitable for the majority of patients with hepatitis C. Recent advances in understanding the replication cycle of hepatitis C virus (HCV) and structural, crystallographic definitions of components of the viral polyprotein have improved the prospects for development of novel therapies. The lack of a small animal model of HCV infection continues to hamper progress in the preclinical evaluation of new antivirals and vaccines. Strategies to enhance response to current therapies include the development of novel interferons and delivery systems, nucleoside analogues that have reduced hemolysis compared with ribavirin, inosine 5' monophosphate dehydrogenase inhibitors, and other immunomodulators that are being evaluated as adjunctive therapy to interferon-based regimens. Compounds in preclinical or early phase human trials include small molecules that inhibit virus specific enzymes (such as the serine proteases, RNA polymerase and helicase), or those that prevent translation initiation (such as antisense molecules and ribozymes). Antifibrotic agents are also being developed in an attempt to prevent disease progression in patients in whom HCV RNA cannot be eradicated. While the advent of these newer compounds represent an exciting phase in the treatment of HCV, their safety and efficacy need to be established. Most of these newer therapies are unlikely to be available for routine clinical use in the next 3 to 5 years.

Duke Scholars

Published In

Hepatology

DOI

ISSN

0270-9139

Publication Date

November 2002

Volume

36

Issue

5 Suppl 1

Start / End Page

S245 / S252

Location

United States

Related Subject Headings

  • Humans
  • Hepatitis C
  • Gastroenterology & Hepatology
  • Gastroenterology
  • Antiviral Agents
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McHutchison, J. G., & Patel, K. (2002). Future therapy of hepatitis C. Hepatology, 36(5 Suppl 1), S245–S252. https://doi.org/10.1053/jhep.2002.36795
McHutchison, John G., and Keyur Patel. “Future therapy of hepatitis C.Hepatology 36, no. 5 Suppl 1 (November 2002): S245–52. https://doi.org/10.1053/jhep.2002.36795.
McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S245–52.
McHutchison, John G., and Keyur Patel. “Future therapy of hepatitis C.Hepatology, vol. 36, no. 5 Suppl 1, Nov. 2002, pp. S245–52. Pubmed, doi:10.1053/jhep.2002.36795.
McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S245–S252.
Journal cover image

Published In

Hepatology

DOI

ISSN

0270-9139

Publication Date

November 2002

Volume

36

Issue

5 Suppl 1

Start / End Page

S245 / S252

Location

United States

Related Subject Headings

  • Humans
  • Hepatitis C
  • Gastroenterology & Hepatology
  • Gastroenterology
  • Antiviral Agents
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1101 Medical Biochemistry and Metabolomics